【新唐人2014年08月14日讯】中共湖南省纪委一名官员，日前在网上实名举报，中共前国家食品药品监督管理局局长邵明立，在将中药“金银花”改名为“山银花”的过程中，扮演利益集团的代言人，导致上千万花农遭受巨大经济损失。有分析指出，邵明立涉中共活摘器官罪恶，背后有保护伞，总能逃过究责，而举报者却屡遭迫害。
8月12号，湖南省纪委预防腐败室副主任陆群，用实名认证微博账号“御史在途”，连发13条微博，指称在邵明立的一手操控下，2005年前后，国家药典委把中国南方地区传承上千年的“金银花”更名为“山银花”，把“金银花”作为邵明立老家山东“忍冬花”的专用名。
公开资料显示，邵明立是山东人，曾任卫生部药政管理局副局长、局长，国家食品药品监督管理局副局长，2005年6月升任局长，2008年3月，任卫生部副部长。前年2月，被免去卫生部副部长、国家药监局局长职务，转任国家药典委常务副主任委员。
陆群在微博中说，品质优良的南方金银花被更名后，价格一落千丈。北方金银花贩子趁机大量低价收购，冒充北方金银花高价卖出，牟取暴利，而南方上千万花农则血本无归。
前湖南药品公司推销退休干部夏先生：“2005年以后，他们更名叫山银花，医生不知道，社会不承认，市场不认可，所以我们的金银花就没有市场了。”
陆群还说，为了搞垮南方金银花产业，以山东“九间棚”为代表的无良企业斥巨资公关，先修改国家药典，再造谣毁谤南方金银花“上火”。造谣的重庆某文化传播公司，已经承认收取“九间棚”130万元的费用。而国家食药监总局的官员们收了多少黑钱，只有他们自己知道。
陆群表示，他将以铁的证据，揭露国家药监局的腐败问题。
湖南省纪委预防腐败室副主任陆群：“国家药监局把南方地区的金银花修改名字，改成山银花，他没任何的依据，你看他公开回应上面说那几个理由，根本不成立，我会在接下来的第一时间内，我会驳斥他们，证明他们那个是一派谎言，实际上就是国家药监局各地的官员，他被利益集团操控了，为利益集团代言。这个事情，我都会摆出来的。”
陆群的微博引发网民热烈讨论。有网友说，事实如何请国家公开调查，给民众一个交代。还有一些网友担心陆群的安危，叮咛他要注意安全。
美国《大纪元》新闻网专栏作者周晓辉指出，事实上，早在国家药监局前局长郑筱萸2007年因受贿被处死刑后，邵明立就曾被举报，举报者是曾担任《中国消费者报社》等媒体特约记者的高纯。
高纯举报说，郑筱萸之死掩盖了邵明立的罪恶，因为没有人去追究，1995年到国家药监局成立之前的1998年，国家药政局局长邵明立是怎样卖药品批文的，没有人去追究，此后国家药监局到底卖出了多少批文。
西安药厂推销员邹先生：“作为药监局那些高层来说，他们过去就是滥批药物，比如说一些药物，厂家生产出来以后，在一个省内要中标。所以在这个方面就是说，能批下来这个生产许可这类东西，本身应该是很严格的，但是他们一天就批几个或几天就批一个，这种做法倒是常见。”
周晓辉表示，一系列造成许多人死亡和残疾的食品药品事件，都发生在邵明立主政期间，但他却每每逃脱被追责。到底谁在罩着邵明立？而高纯却因持续举报，多次遭迫害。
周晓辉透露，邵明立与“瑞士诺华制药公司”关系密切，与“瑞士罗氏制药公司”的交集也有迹可寻。而这两家公司生产的抑制免疫力药剂，广被中国的肾移植患者使用。
2005年1月至2006年6月，诺华公司用300人作肾实验，实验地点是被怀疑活摘、移植法轮功学员器官的“上海第一人民医院”。
周晓辉指出，“瑞士诺华制药”与“罗氏制药”在中国迅速发展，与中共活摘法轮功学员器官的罪恶是分不开的，而主管药品审批的邵明立摆脱不了自身的罪恶。
采访/陈汉 编辑/陈洁 后制/李勇
Real Name Report On Food and Drug Administration Director
A Hunan Provincial Commission for Discipline Inspection
official recently issued a report online regarding former
Director of the State Food and Drug Administration,
Shao Mingli, using his real name.
Shao was said to have played a key role in changing
the name of a famous Chinese herb.
He served as a representative for the herb that replaced
a well-known herb, causing huge economic loss of tens
of millions of growers.
Analysts point out that Shao Mingli has been involved
in the CCP’s organ harvesting.
His umbrella of protection has always helped to him avoid
charges, but the informants are always persecuted.
On Aug. 12, deputy director of the Prevention of Corruption
of Hunan Provincial Commission for Discipline Inspection,
Lu Qun, issued 13 blog statements regarding Shao Mingli
with his real name.
He indicated that Shao changed the name of a southern
Chinese herb, Jin-yin-hua, to San-yin-hua.
Shao also specified the herb to be Jin-yin-hua
in his hometown in Shandong.
Shao Mingli is a Shandong native.
He held various posts at the Ministry of Health
and the state Food and Drug Administration.
In June 2005 he was promoted to Director of the FDA
and in March 2008 he served as Deputy Minister of Health.
In Feb. 2012, he was dismissed from the Ministery of Health
and the FDA, but transferred to the State Pharmacopoeia
Commission as Deputy Chairman.
Lu Qun stated in the blog that after the name change,
the price of good quality Southern Jin-yin-hua plummeted.
Northern traders took the opportunity to acquire the herb
at low cost and sell at high prices as the northern herb.
Tens of millions of southern growers were left to endure
a tremendous economic loss.
Mr. Xia, a retiree from a Hunan drug company:
“Since the herb was renamed in 2005, doctors,
society and the market do not recognize the new name.
Jin-yin-hua was left with no market."
Lu Qun wrote that in order to bring down the Southern
Jin-yin-hua industry, Shandong’s industry spent huge sums
on public relations to change the name through
the national pharmacopoeia.
They then spread rumors to slander the southern Jin-yin-hua
as causing side effects.
A Chongqing public relations company admitted to accepting
a 1.3 million yuan PR fee to publicize the rumors.
The amount of bribery FDA officials have received
is unknown.
Lu Qun indicates that he will expose the corrupt FDA
with solid evidence.
Lu Qun: “The State FDA baselessly renamed the southern
Jin-yin-hua as San-yin-hua.
The publicized responses do not sustain.
I will refute them quickly and prove them lying.
In fact, the entire FDA at local levels has endorsed for local
interest groups and have been controlled by interest groups.
I will show all the evidence."
Lu Qun’s blogs have sparked heated discussion
among netizens.
Some demanded public investigation.
Others worried for Lu Qun’s safety.
The Epoch Times columnist Zhou Xiaohui indicates that as
early as when former Director of FDA Zheng Xiaoyu
was executed for taking bribes in 2007, Shao Mingli had been
reported by a China Consumer News journalist, Gao Chun.
Gao Chun reported that Zheng Xiaoyu’s death has masked
Shao Mingli’s crimes.
Between 1995 and 1998, no one questioned how Director
of FDA Shao Minli approved the sale of the drug.
Mr. Zou, Xi’an pharmaceutical salesman (voice modified):
“The high State FDA officials abused the approval process.
For instance, the manufacturers delivered the drugs
for approval.
The process of getting a license should be very strict.
But, they would just do it randomly, a few in a day
or sometimes one every few days.
It is very common."
Zhou Xiaohui indicates that a series of fatalities and
disabilities caused by food and drug have occurred during
Shao Mingli’s power, but he often escaped being
held accountable.
Who is covering for Shao Mingli while Gao Chun has been
repeatedly persecuted for his persistent reports on Shao?
Zhou Xiaohui reveals that Shao Mingli has close ties
to Novartis Pharmaceuticals.
He also had interactions with the Swiss pharmaceutical
company Roche.
The immunosuppressive agents produced by these two
companies are widely used by China’s kidney transplant patients.
Between January 2005 and June 2006, Novartis conducted
a kidney test on 300 people.
The test was done in Shanghai First People’s Hospital,
a hospital alleged to be engaged in organ harvesting
from living Falun Gong practitioners.
Zhou Xiaohui points out that rapid development of Novartis
and Roche in China is inseparable from the CCP crime’s
of organ harvesting from living Falun Gong practitioners.
Shao Mingli, responsible for the drug approval,
cannot escape from his sins.
Interview/ChenHan Edit/ChenJie Post-Production/LiYong
